Morgan Stanley Institutional Vitality Portfolio (MSVDX)
| Fund Assets | 1.89M |
| Expense Ratio | 0.95% |
| Min. Investment | $5,000,000 |
| Turnover | 19.00% |
| Dividend (ttm) | 0.00 |
| Dividend Yield | 0.08% |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | Dec 11, 2024 |
| Previous Close | 5.37 |
| YTD Return | -6.37% |
| 1-Year Return | -11.76% |
| 5-Year Return | n/a |
| 52-Week Low | 4.85 |
| 52-Week High | 6.58 |
| Beta (5Y) | n/a |
| Holdings | 37 |
| Inception Date | Dec 31, 2021 |
About MSVDX
Morgan Stanley Institutional Fund, Inc. Vitality Portfolio Class I is an actively managed mutual fund that targets long-term capital appreciation by investing primarily in U.S.-based healthcare companies. The fund's core strategy is to seek out firms engaged in the discovery, development, production, or distribution of products and services that capitalize on advances in healthcare. Its investment process emphasizes identifying businesses with sustainable competitive advantages, strong research and development capabilities, and robust new product pipelines. Major holdings often include leading pharmaceutical, biotechnology, and healthcare equipment companies. This portfolio adopts a conviction-weighted approach, resulting in a concentrated mix of holdings, with over half of assets typically allocated to its top ten investments. Managed by an experienced team with deep industry expertise, the fund plays a specialized role within the financial market by offering exposure to innovation within the dynamic healthcare sector. Its focus makes it relevant for investors seeking targeted access to healthcare trends and companies driving medical and scientific advancement.
Performance
MSVDX had a total return of -11.76% in the past year, including dividends. Since the fund's inception, the average annual return has been -4.38%.
Top 10 Holdings
55.32% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 9.02% |
| Argenx SE | n/a | 7.67% |
| UnitedHealth Group Incorporated | UNH | 6.11% |
| Vertex Pharmaceuticals Incorporated | VRTX | 5.27% |
| Exact Sciences Corporation | EXAS | 5.12% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 4.86% |
| Thermo Fisher Scientific Inc. | TMO | 4.84% |
| Intuitive Surgical, Inc. | ISRG | 4.69% |
| Ascendis Pharma A/S | ASND | 4.19% |
| Zoetis Inc. | ZTS | 3.55% |